Hyperfine (HYPR) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenue of $3.63 million, up 7.4% year-over-year, driven by balanced U.S. and international sales and strong commercial traction.

• FDA clearance of ninth-generation AI-powered software enhanced imaging capabilities and clinical performance, reducing scan times.

• Progressed clinical studies in Alzheimer's and stroke, with promising initial data and growing interest from major programs.

• Expanded distribution to 12 EU markets, India, and other international regions, with new office and regulatory submissions underway.

• Cash and cash equivalents stood at $53.8 million as of June 30, 2024, supporting ongoing R&D and commercial expansion.

Financial highlights

• Q2 2024 revenue was $3.63 million, up 7.4% year-over-year; six-month revenue reached $6.93 million, up 15.1% year-over-year.

• Gross margin reached a record 49.7% in Q2 2024, with gross profit of $1.8 million.

• R&D expenses were $5.96 million in Q2 2024; SG&A expenses decreased to $6.69 million from $7.81 million year-over-year.

• Net loss improved to $10.16 million ($0.14/share) in Q2 2024 from $10.64 million ($0.15/share) year-over-year.

• Cash burn for Q2 2024 was $9.4 million; net cash used in operating activities for the first half was $22.0 million.

Outlook and guidance

• FY 2024 revenue guidance raised to $13–16 million, reflecting strong momentum in U.S. and international channels.

• Full-year gross margin expected in the 45–50% range; cash burn for 2024 anticipated at ~$40 million.

• Cash runway projected into early 2026, supporting growth initiatives.

• Expects continued commercial progress in H2 2024, with some summer seasonality impact and revenue contributions from new office and international business in H2 2025.

• Management expects ongoing net losses and cash burn until product and service sales generate sufficient gross profit.